Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

PHASE4CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

June 17, 2013

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2022

Conditions
Rheumatoid Arthritis
Interventions
DRUG

TNF inhibitors

DRUG

Synthetic DMARD(s)

DRUG

Co-medication: Synthetic DMARDs

Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.

Trial Locations (10)

1306

Martina Hansens Hospital AS, Sandvika

1603

Department of Rheumatology, Sykehuset Østfold HF, Fredrikstad

2609

Revmatismesykehuset AS, Lillehammer

3004

Department of Rheumatology, Drammen Hospital, Vestre Viken HF, Drammen

4604

Department of Rheumatology, Sørlandet Sykehus HF, Kristiansand

5021

Department of Rheumatology, Haukeland University Hospital, Helse Bergen HF, Bergen

6026

Department of Rheumatology, Helse Møre og Romsdal HF, Ålesund

8613

Helgelandssykehuset, Mo i Rana, Mo i Rana

9038

Universitetssykehuset Nord-Norge HF, Tromsø

0319

Department of Rheumatology, Diakonhjemmet Hospital, Oslo

All Listed Sponsors
collaborator

The Research Council of Norway

OTHER

collaborator

South-Eastern Norway Regional Health Authority

OTHER

lead

Diakonhjemmet Hospital

OTHER

NCT01881308 - Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter